2 Bath Place
About Gyroscope TherapeuticsGyroscope Therapeutics is a private company founded by Syncona and Cambridge Enterprise and supported by its scientific founders with expertise in ophthalmology, immunology and gene therapy.
Our mission is to develop genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system.
Our management and scientific teams have extensive experience in gene therapy and drug development, particularly in the field of ophthalmology, and have served in leadership roles at several innovative pharmaceutical companies.
April 16, 2016
Founders: Syncona and Cambridge Enterprise
CEO: Dr. Soraya Bekkali
Please click here for Gyroscope Therapeutics' job opportunities.
24 articles with Gyroscope Therapeutics
Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company focused on treating diseases of the eye, announced it has postponed plans for its initial public offering.
5/5/2021April showers bring May dollars. Here's whose cash gardens are really blooming this week in the life sciences world.
Two weeks after announcing plans for initial public offerings, Gyroscope Therapeutics and Talaris Therapeutics have now set the terms for their debut on the Nasdaq.
Gyroscope Therapeutics Holdings plc (“Gyroscope”), a clinical-stage gene therapy company focused on treating diseases of the eye, today announced that it has launched the roadshow for its initial public offering in the United States of up to 6,750,000 American Depositary Shares (“ADSs”) representing 6,750,000 ordinary shares.
Six months after bagging $115 million in a Series B financing round, Talaris Therapeutics is aiming to raise another $100 million through in initial public offering. It’s one of three companies joining in the flurry of IPOs this week.
Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States
Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.
3/31/2021Over $700 million dropped into IPO biotech stock this week, with hundreds of millions more pouring into company financing rounds. Here are some of the top earners this past week.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced that it expects to consider additional capital raising options this year, which could include an initial public offering in the United States.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye, announced it has raised USD $148.0 million in a Series C financing.
The financing involves Forbion’s Growth Opportunities Fund and includes its founding cornerstone investor, Syncona Investment Management Limited, which provided $42.3 million in investment.
3/5/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on diseases of the eye, announced the appointment of Jessica Stitt as Chief Financial Officer, effective immediately.
Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005
Interim Data Showed GT005 Was Well Tolerated in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) Majority of Patients Treated with GT005 Had Increases in Complement Factor I (CFI) Levels, with an Average Increase of 146% Compared to Baseline Interim Data Demonstrated Potential for Single Administration of GT005 to Down-Regulate Overactive Complement System, a Key Driver of AMD
Gyroscope Therapeutics Announces Appointments of Industry Veterans in Gene Therapy, Ophthalmology and Biopharmaceuticals to Its Board of Directors
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, today announced that Jennifer Cook, David Fellows and Renée Galá have been appointed to the Gyroscope Board of Directors, effective immediately. “I am very pleased to welcome Jennifer, David, and Renée, three extremely accomplished executives with extensive biopharmaceutical backgrounds, to our board of directors,” said Khurem Farooq, Chief Executi
Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
U.S. FDA Grants Second Fast Track Designation to GT005 for Treatment of Geographic Atrophy
Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial
Gyroscope Therapeutics Limited announced that the first surgery using its proprietary Orbit™ Subretinal Delivery System to deliver the company’s investigational gene therapy, GT005, to a patient with geographic atrophy secondary to dry age-related macular degeneration has been conducted in the ongoing Phase I/II FOCUS trial.
Gyroscope Therapeutics Granted FDA Fast Track Designation for GT005, an Investigational Gene Therapy for Dry Age-Related Macular Degeneration
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food and Drug Administration has granted Fast Track designation to GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration.
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that biotech industry veteran Sean Bohen, M.D., Ph.D., has been appointed to the Gyroscope Board of Directors, effective immediately.
Gyroscope Therapeutics Limited, a clinical-stage retinal gene therapy company, announced that the U.S. Food & Drug Administration has granted 510 clearance for the Orbit™ Subretinal Delivery System.
8/17/2020It was a very busy week for clinical trial updates. Here’s a look.